People | April 29, 2026
NADMED Limited appoints James Lee as CEO to drive global expansion
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities
The approval was driven by data from the Phase III TULIP-SC trial
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
